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Abstract
Heparanase is an endo-B-glucuronidase that is capable
of degrading heparan sulfate chains of proteoglycans,
generating a variety of bioactive molecules such as
growth factors and chemotactic and angiogenic agents.
The expression of heparanase was investigated in
the peripheral blood mononuclear cell fraction (PBMC)
of 30 patients with breast cancer and 20 healthy con-
trol women by reverse transcription–polymerase chain
reaction (RT-PCR) and immunocytochemistry. PBMC
samples from all breast cancer patients at study entry
showed the expression of heparanase, whereas no
expression was observed for healthy women. Immuno-
cytochemistry analysis demonstrated that heparanase
was expressed in lymphocytes of breast cancer PBMC.
Throughout follow-up, heparanase expression by RT-
PCR decreased significantly after surgery in patients
treated with neoadjuvant chemotherapy (P = .002) and
after tamoxifen treatment (P = .040), whereas it in-
creased significantly with the advent of systemic me-
tastasis (P = .027). In vitro, either serum from breast
cancer patients or a medium originated from co-
culture experiments of MCF-7 cells and lymphocytes
from healthy women stimulated heparanase expres-
sion in normal lymphocytes. The results suggest that
there is a tumor-inducing effect on heparanase expres-
sion by lymphocytes present in the PBMCs of breast
cancer patients, which depends, in turn, on the inter-
action between a tumor and normal lymphocytes.
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Introduction
Solid tumors have three compartments: malignant cells,
microcirculation, and stroma. There is a close interchange
among all these components through paracrine and autocrine
mechanisms involving cells from all these three compart-
ments. As a result of this intricate cellular and humoral network,
there is a change in the expression of various genes of cells
belonging to all these three compartments, which act in con-
cert and are responsible for malignant cell proliferation, apop-
tosis, angiogenesis, tumor cell invasion, and metastasis [1]. In
addition to normal cells present in the stroma, breast cancer
and other solid tumors also have variable amounts of tumor-
infiltrating lymphocytes (TILs). In fact, breast cancer tumors
infiltrated more prominently by TILs seem to have better
prognosis [2]. Therefore, it is possible that TILs, in addition
to their immune-related functions [3], may actively participate
in the aforementioned network by actively secreting and re-
sponding to cytokines produced by tumors, endothelial cells, or
stromal cells [4,5].
Heparan sulfate proteoglycans are found in extracellular
matrices and on cell surfaces, playing critical functions in cell–
cell and cell–matrix interactions [6,7]. In fact, transmembrane
heparan sulfate proteoglycans (syndecans) are emerging as
molecules that mediate cell interactions with components of
the microenvironment that control cell shape, adhesion, pro-
liferation, and differentiation [8,9]. Additionally, cell-associated
heparan sulfate can potentiate the interaction of soluble
growth factors with cell surface receptors, and its binding can
also protect growth factor cleavage by proteolytic enzymes
[10,11]. Furthermore, heparan sulfate proteoglycans are also
prominent components of endothelial cells [12] and the base-
ment membrane [13].
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Heparanase is an endo-b-glucuronidase that is capable of
degrading heparan sulfate chains of proteoglycans, a key
component of the extracellular matrix and the basement
membrane. The oligosaccharides so generated lead to the
release of a variety of bioactive molecules, such as growth
factors, chemotactic agents, and angiogenic agents, which
are then deposited in the extracellular matrix and basement
membrane. These molecules can stimulate cell proliferation,
increase cell survival, and promote angiogenesis, morpho-
genesis, and vascularization [14]. Fragments of heparan sul-
fate generated by heparanase can also induce the maturation
of dendritic cells and activate macrophages, thereby stimu-
lating the release of factors such as IL-1, IL-6, and pros-
taglandin E2, which modulate immune cell responses [15,16].
Furthermore, protein or messenger RNA (mRNA) expression
of heparanase has been identified in various cancer cells, and
its overexpression in tumor cells has also been reported to cor-
relate with metastatic potential and poorer prognosis [17,18].
In the present study, the expression of heparanase in the
peripheral blood mononuclear cell (PBMC) fraction of breast
cancer patients was analyzed serially with semiquantitative
reverse transcription–polymerase chain reaction (RT-PCR).
We also report a series of in vitro assays to investigate pos-
sible mechanisms of the alterations in heparanase expres-
sion found in these patients. A panel of other proteins that
are commonly altered in tumors—such as those involved
in DNA mismatch repair (hMLH1, hMLH2, hPMS1, and
hPMS2) [19] and those involved in cell proliferation and
apoptosis (PCNA and P53) [20,21]—was also investigated.
Patients and Methods
Patients
Blood samples from 30 patients with histologically con-
firmed breast cancer were obtained after informed consent
had been granted. From these patients, serial samples were
collected at 3-month intervals before, during, and after
systemic treatment (13 adjuvant, 12 neoadjuvant, and 5 pal-
liative). Three patients initially received hormones (two
adjuvantly and one palliatively). The chemotherapy combi-
nations used in these patients were as follows: 5-fluorouracil,
adriamycin, and cyclophosphamide; adriamycin and cyclo-
phosphamide; and cyclophosphamide, methotrexate, and
5-fluorouracil. Peripheral blood samples were also collected
at 3-month intervals from 20 healthy control women without
any relevant previous medical history. The present study
conformed to the regulations of The Human Ethic Research
Committee at our institution, ABC School of Medicine (proj-
ect no. 2000/04681-2).
mRNA Extraction and RT-PCR Analysis
Peripheral blood samples (20 ml) were collected every
3 months using EDTA. Mononuclear fractions were prepared
using Ficoll Hypaque gradient (Teknica, Durham, NC). A total
of 1  106 lymphocytes/ml was submitted to RNA extrac-
tion using Trizol reagent (Invitrogen, Carlsbad, CA) following
the manufacturer’s instructions. The integrity of total RNA
was checked electrophoretically and quantified spectropho-
tometrically. Complementary DNA (cDNA) was synthesized
from 5 mg of total RNA in a 25-ml reaction (Invitrogen) con-
taining 1 ml of oligod(T)18 (0.5 mg/ml), 1 ml of dNTPs (10 mM),
and 1 of ml reverse transcriptase (Invitrogen) Moloney Murine
Leukemia Virus (M-MLV), and the reaction was performed
at 42jC for 30 minutes. For PCR amplification, 2 ml of cDNA
previously obtained by reverse transcription reaction and
Master Mix reagents (Promega, Madison, WI) was used.
Heparanase was amplified using forward (5V-CCCGAATTCA-
AAAAGTTCAAGAACAGCACC-3V) and reverse (5V-CCATG-
GTCAAGTGCAAGCAGCAACTTTGGC-3V) primers, and the
product obtained was 1284 bp. PCR was run for 95jC for
10 minutes, followed by 35 cycles of 95jC for 1 minute, 55jC
for 1 minute, and 72jC for 2 minutes. The primers 5V-AA-
CGGGAAGCTCACTGGCATG-3V (forward) and 5V-TCCA-
CCACCCTGTTGCTGTAG-3V (reverse) were used to amplify
glyceraldehyde-3-phosphate dehydrogenase (GAPDH),
which yielded a product of 378 bp. PCR conditions were as
follows: 1 cycle at 95jC for 10 minutes, followed by 35 cycles
of 95jC for 30 seconds, 58jC for 30 seconds, and 72jC for
30 seconds. Products amplified by RT-PCR were analyzed
by agarose gel electrophoresis, and each cDNA band was
quantified by densitometry using the ImageTool analysis pro-
gram (University of Texas Health Science Center in San
Antonio, San Antonio, TX).
MCF-7 Cells
An established human breast cancer cell line (MCF-7)
was cultured using Dulbecco’s medium Eagle’s medium (Life
Technologies, St. Louis, MO) with added 1.2 g/l NaHCO3,
0.1 g/ml streptomycin, 0.025 g/ml penicillin, and 10% fetal
bovine serum in a humidified incubator at 37jC in the pres-
ence of 5% CO2.
Immunocytochemistry
All antibodies were supplied by Santa Cruz Biotechnology
(Santa Cruz, CA). For immunostaining, we used an avidin–
biotin–peroxidase complex and 3,3V-diaminobenzidine as
chromogen. The following dilutions were used for each
antibody: HPA1 C-20 (anti–heparanase 1) and HPA2 C-17
(anti–heparanase 2), 1:100; PC-10 (anti-PCNA), 1:1000;
C-20 (anti-hMLH1), 1:25; K-20 (anti-hPMS1), 1:25; C-20
(anti-hPMS2), 1:200; N-20 (anti-hMSH2), 1:200; Pab1801
(anti-P53), 1:400. The preparation of immunocytochemistry
slides has been described in detail by Fonseca et al. [22].
Two independent observers scored 300 cells/slide as posi-
tive or negative according to the presence of staining for
each of the abovementioned antibodies. The results from
these two observers were averaged to obtain the percen-
tages of positive cells per sample.
Stimulatory Heparanase Assay in the Mononuclear
Fraction of Peripheral Blood Samples
Lymphocyte fractions from healthy women were incu-
bated with plasma or serum from breast cancer patients
or with conditioned medium collected from MCF-7 cells for
4 hours at room temperature. In a coculture assay, MCF-7
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cells were preincubated overnight with mononuclear frac-
tion from a healthy woman’s peripheral blood sample, and
the conditioned medium collected was then incubated for
4 hours at room temperature with another mononuclear
fraction from a healthy woman. It is important to point out
that PBMCs used during the preincubation of coculture
assays with MCF-7 cells were depleted of monocytes due
to the preliminary differentiation of this cellular fraction using
40 nM phorbol 12-myristate 13-acetate (PMA) during 8 hours
of incubation. This procedure of PBMC incubation using
PMA promoted the differentiation of monocytes into macro-
phages, which became attached to culture plates, whereas
lymphocytes were recovered from the supernatant and used
for coculture incubation with MCF-7 cells overnight. Control
assays were performed by the incubation of a healthy
woman’s PBMCs with a sample from the mononuclear
fraction of another healthy woman.
Statistical Analysis
Statistical analysis was performed with the SPSS 13.0
program for Windows (SPSS, Chicago, IL). Variables in the
study were considered parametric using the Kolmogorov-
Smirnov test. Therefore, t-tests and paired t-tests were used.
Results
Serial Semiquantitative Heparanase RT-PCR in Peripheral
Blood: A Marker for Breast Cancer Disease and Recurrence
In the present study, 30 patients with breast cancer and a
mean age of 52 years (range, 25–80) were enrolled. Twelve
patients had stage II breast cancer, 13 patients had stage III
breast cancer, and 5 patients had stage IV breast cancer.
The 20 normal control samples had a mean age of 50 years
(range, 22–70). The expression of heparanase was present
in PBMC samples analyzed from all 30 breast cancer pa-
tients (133.44 ± 53.44), whereas no expression was ob-
served in the mononuclear fraction of 20 healthy women
(Figure 1). Interestingly, heparanase expression detected by
semiquantitative RT-PCR varied throughout the follow-up
period of breast cancer patients (Figure 1), whereas no
change in expression was observed in the samples of control
healthy women collected at 3-month intervals (Figure 1).
When we attempted to correlate the variations of hepa-
ranase expression in positive PBMCs of breast cancer pa-
tients in relation to their clinical characteristics, we observed
that: 1) heparanase expression decreased significantly after
surgery (P = .002) in patients who underwent surgical removal
of their tumors after neoadjuvant chemotherapy (Table 1);
2) heparanase expression was significantly higher in the
PBMCs of metastatic patients receiving palliative treatment
than in those with early breast cancer postsurgery (P = .011)
(Table 1); and 3) heparanase expression increased signifi-
cantly with the appearance of systemic metastasis (81.01 ±
17.01 before the metastatic event vs 142.90 ± 59.71 after the
diagnosis of metastasis; P = .027) (Table 1).
Taken together, the above observations pointed toward
the possibility that the presence of breast cancer tumor was
associated with heparanase overexpression in PBMCs. We
also observed a significant decrease in heparanase expres-
sion during tamoxifen treatment compared to chemotherapy
or radiation therapy (P = .040) (Table 1).
Identification of Cells Expressing Heparanase in the
PBMC Fraction By Immunocytochemistry
To ascertain which of the cells of PBMCs expressed
heparanase, we used immunocytochemistry and polyclonal
antibody anti-heparanase (HPA1 C-20). It can be observed in
Figure 2 that lymphocytes from healthy women did not ex-
press heparanase 1, whereas breast cancer patients’ lympho-
cytes expressed > 95% of heparanase 1 (HPA1). These data
Table 1. Clinical Characteristics and Heparanase Expression Measured By
RT-PCR in the Mononuclear Fraction of Breast Cancer Patients.
Event Heparanase Expression P
Surgery
Before 169.21 ± 45.40 .002
After 104.73 ± 46.25
Adjuvant-versus-palliative treatment
Free from disease 91.95 ± 54.61 .011
Palliative treatment 155.53 ± 45.58
Metastasis or recurrence
Before 81.01 ± 17.01 .027
After 142.90 ± 59.71
Type of treatment
Chemotherapy or radiotherapy 136.28 ± 57.32 .040
Tamoxifen 78.82 ± 54.20
Numbers indicate the mean of heparanase expression and standard devi-
ation. P indicates a comparison of means between patients’ initial sample
values and healthy women’s heparanase expression.
Figure 1. Heparanase expression in the mononuclear fraction of peripheral blood samples. (I) Semiquantitative RT-PCR heparanase expression in themononuclear
fraction of breast cancer patients and healthy women. (II) Agarose gel electrophoresis: heparanase (A andC) andGAPDH (B andD). (A and B) Different samples from
patients IMMP (1–6) and MBD (7–11). (C and D) Different samples from healthy women. Each sample was collected at 3-month intervals.
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confirmed previous results obtained by semiquantitative RT-
PCR where heparanase expression was analyzed by specific
HPA1 primers.
We also investigated the expression of heparanase
2 (HPA2) in PBMCs using HPA2C-17; interestingly, compared
with the results obtained for HPA1, similar results were
obtained. It was shown that 72% of breast cancer patients’
lymphocytes were positive for heparanase 2 polyclonal anti-
body (HPA2 C-17), whereas only 8% of healthy women’s lym-
phocytes were stained using the same technique (Figure 2).
Costimulation Experiments with Healthy
Women’s Lymphocytes
It is important to point out that the expression of hepa-
ranases HPA1 and HPA2 in the lymphocyte fraction of PBMCs
was analyzed by immunocytochemistry, as described in
Patients and Methods, and experimental conditions were
derived from time-dependent and temperature-dependent
curves to define the ideal condition for the incubation of
mononuclear fraction lymphocytes to standardize the ex-
periments (data not shown). Initially, we observed that both
MCF-7 breast cancer cells and plasma from breast cancer
patients were independently able to stimulate the expression
of both heparanases in the lymphocytes of PBMCs from a
healthy woman’s mononuclear fraction cells incubated for
4 hours at room temperature (Figure 2). In contrast, no in-
crease in heparanase expression was observed when the
mononuclear fraction of a healthy woman’s lymphocytes was
incubated with another sample of PBMCs or with plasma
from another healthy woman, showing that the observed
activation of heparanase expression shown in previous ex-
periments could not be related to exposure to a different in-
dividual plasma or PBMC preparation. Furthermore, similar
experiments using sera from patients with breast cancer also
induced an overexpression of both heparanases by PBMC
lymphocytes from healthy women (data not shown).
Coculture of MCF-7 Cells and Lymphocytes from
Healthy Women
Because MCF-7 cells in contact with a healthy woman’s
PBMCs induced an increase in HPA1 and HPA2 expres-
sion, the conditioned medium from MCF-7 cells was added
to a healthy woman’s PBMCs. The conditioned medium from
MCF-7 cells was not able to stimulate a healthy woman’s
PBMCs when incubated for 4 hours at room temperature
(Figure 3).
To evaluate whether cells from PBMCs would intermediate
the effects of tumoral cells on the overexpression of both
heparanases by normal lymphocytes, a new assay was de-
veloped. This assay involved initially coculturing MCF-7 cells
with PBMCs from a healthy woman (18 hours, at 37jC, 5%
CO2). Then the conditioned medium collected from this co-
culturewas assayedwith another healthy woman’s PBMCs for
4 hours at room temperature (Figure 3). Interestingly, the re-
sults have shown that themedium obtained from the coculture
of MCF-7 cells and a healthy woman’s PBMCs was able to
stimulate HPA1 and HPA2 expression in the lymphocytes of
another sample of PBMCs from a healthy woman (Figure 3).
We attempted to evaluate whether monocytes from
PBMCs were the cells responsible for enriching the medium
in the previous coculture in such a way as to lead to the in-
crease in heparanase expression. Monocytes were removed
from the PBMC fraction through their adherence to the
surface of culture plates after treatment with PMA, and it
was observed that there was still HPA1 and HPA2 over-
expression induction mediated by the coculture of MCF-7
cells and PBMC fraction from a normal subject who was now
poor in monocytes (data not shown).
Immunocytochemistry Analysis of PBMCs Using Other
Tumor Markers
Finally, we decided to evaluate whether changes in the
gene expression of PBMCs would be restricted to hepa-
Figure 2. Stimulatory effect of heparanase expression in PBMCs. Analyses were performed by immunocytochemistry using the antibodies anti-heparanase (HPA1
C-20; black) and anti –heparanase 2 (HPA2 C-17; white). Both antibodies were purchased from Santa Cruz Biotechnology, as described in Patients and Methods.
(A) Breast cancer patients’ mononuclear fraction cells (PBMCs). (B) A healthy woman’s PBMCs. (C) A healthy woman incubated with plasma from a breast cancer
patient. (D) A healthy woman’s PBMCs incubated with MCF-7 cells. (E) MCF-7 cells.
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ranases or could also happen for other proteins that are also
important for tumor development. Thus, PBMC samples
from the same breast cancer patients and from healthy
women previously evaluated for heparanase expression
were then investigated for PCNA, P53, hMLH1, hPMS1,
hPMS2, and hMSH2. We observed significant differences
in the expression of PCNA (P = .031), hMSH2 (P = .018), and
hPMSH2 (P = .017) between healthy women and breast
cancer patients (Table 2). No significant differences were
observed in the expression of the aforementioned proteins
between the initial samples and the repeated samples of
the same healthy women collected 3 months later (Table 2).
Discussion
It is important to point out that the gene encoding HPA1maps
to human chromosome 4q21.3, whereas human chromo-
some 10q23–24 encodes three alternative splice variants of
HPA2. Despite being encoded by different chromosomes,
the expression of both heparanases in the lymphocytes of
PBMCs of healthy women was stimulated by plasma, serum,
or tumor cells. These results could suggest that possibly
heparanase isoforms present at least one mechanism of
gene control in common.
Our data further suggest that this tumor-inducing effect
on both HPA1 and HPA2 expression is not directly medi-
ated by tumor cells, but depends on the presence of non-
neoplastic cells in PBMCs that seem to be lymphocytes and
not monocytes. Additionally, tumor-inducing effects on the
gene expression of PBMCs are not restricted to hepa-
ranases, but can also be shown in genes related to the
DNA repair mechanism, such as hMSH2 and hPMS2, and in
cell proliferation–associated genes, such as PCNA. Taken
together, our data also suggest that a tumor-induced sys-
temic effect, produced through an interaction between tumor
cells and cells present in PBMCs, affects the expression of
several genes from nontumoral cells. Conceivably, these
effects could contribute to enhanced primary tumor growth,
metastasis, and angiogenesis.
In vivo, it is possible that the tumor may induce its
infiltrating lymphocytes (TILs) to produce a factor that, in
the systemic circulation, may in turn lead to changes in gene
Figure 3. Stimulatory effect of heparanase expression by a coculture assay in PBMCs. Analyses were performed by immunocytochemistry using the antibodies
anti-heparanase (HPA1 C-20; black) and anti –heparanase 2 (HPA2 C-17; white), as described in Patients and Methods. Mononuclear fraction cells (PBMCs) from
(A) a breast cancer patient; (B) a healthy woman; (C) a healthy woman incubated with plasma from a breast cancer patient; (D) a healthy woman incubated with the
PBMCs of another sample from a healthy woman; (E) a healthy woman incubated with MCF-7 conditioned medium; (F) a healthy woman incubated with MCF-7
cells for 18 hours (coculture assay); and (G) a healthy woman incubated with coculture conditioned medium.
Table 2. Quantification of Different Proteins Related to Cell Proliferation, DNA Repair, and Apoptosis by Immunocytochemistry Assay.
Immunohistochemistry Reaction NC T0 (n = 20) NC T3 (n = 20) Patients (n = 28) P
PCNA 15.93 ± 4.57 17.20 ± 4.57 31.70 ± 3.86 .031
hMSH2 72.70 ± 4.50 75.81 ± 4.50 56.22 ± 3.80 .018
hMLH1 0 ± 0.21 0 ± 0.21 0.60 ± 0.18 .080
hPMS1 0.60 ± 0.33 0.10 ± 0.33 0.73 ± 0.28 .780
P53 ND ND ND
hPMSH2 0 ± 3.33 0 ± 3.33 12.84 ± 2.81 .017
Numbers represent the mean ± standard deviation of the percentage of positive cells for PCNA, hMSH2, hMLH1, hPMS1, P53, and hPMSH2.
NC = normal controls; T0 = samples obtained initially; T3 = samples obtained after a 3-month interval; SD = standard deviation; N = number of patients; ND = not
detected.
P values reflect a comparisons of means between patients’ initial samples and normal controls’ first samples.
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expression in various non-neoplastic cells and potentially
also in malignant cells because these changes in gene
expression can be induced by treatment with conditioned
media from cocultures of MCF-7 and non-neoplastic PBMCs.
Furthermore, because the expression of heparanase de-
creases in patients with breast cancer rendered free of tumor
by surgery, it is possible that these changes in heparanase
gene expression depend on the dysregulation of gene ex-
pression by reversible mechanisms such as promoter meth-
ylation and promoter inhibition by P53 binding [23,24].
In line with our results, Kataoka et al. [25] showed that
media from cultured rabbit carcinoma cells stimulated the
secretion of interstitial collagenase by fibroblasts. Dabbous
et al. [26,27] also demonstrated that fibroblast-like and
endothelial-like cells derived from carcinoma cultures re-
leased more interstitial collagenase than normal fibroblasts.
In addition, in accordance with this complexity of normal–
tumor cell interactions, Henry et al. [28] showed that co-
cultures of mouse peritoneal macrophages and Lewis lung
carcinoma cells induce the release of a type IV collagen–
degrading metalloproteinase activity and proteoglycan-
degrading enzymes that are not secreted in detectable
amounts by either cell type alone. Dabbous et al. [26,27]
also reported that tumor-associated mast cells stimulated
fibroblasts to secrete interstitial collagenase activity.
It is known that inflammation plays a critical role in cancer
progression, and some studies have demonstrated that mac-
rophage interaction with cancer cells promotes a protumori-
genic activity that changes the gene expression profile in lung
cancer cells [28,29]. In our study, however, our data suggest
that it is the interaction between tumor cells and lymphocytes
that seems to be important for heparanase expression in-
duction by the PBMC fraction in cancer patients.
Interestingly, our data show a significant difference in
heparanase expression in the mononuclear fraction of pe-
ripheral blood samples from breast cancer patients without
evidence of malignancy compared to those from patients
with known active disease and from healthy women. There-
fore, heparanase expression in the PBMCs of breast cancer
patients may be also a marker of disease activity, and fu-
ture studies should be conducted to evaluate this inter-
esting hypothesis.
We also observed a significant decrease in heparanase
expression in PBMCs from patients submitted to tamoxifen
treatment, in comparison to chemotherapy or radiotherapy.
This result could be due to the fact that tamoxifen competes
with estrogen for estrogen receptors that, in turn, when ac-
tivated by estrogen, increase heparanase expression by di-
rectly activating the heparanase promoter [30,31]. So far, our
data have agreed with what has been shown in in vitro
assays using culture cells [30].
As heparanase expression seems to be due to its over-
regulation by normal cells, we do not believe that detection of
heparanase-expressing cells in PBMC fractions necessarily
indicates the presence of circulating malignant cells for
which detection would be useful for minimal residual disease
assessment in these patients. Nevertheless, we cannot ex-
clude that heparanase overregulation in PBMC fractions
may itself be a tumor marker. Further studies are necessary,
however, to confirm this contention.
These studies have demonstrated a possible mechanism
of interaction between tumor cells with PBMCs that activate
heparanase expression by non-neoplastic cells, as well as
other proteins. Whether the cells of PBMCs are only by-
standers of the systemic activation of some of these changes
in gene expression or whether they could be important for
tumor progression is unknown at present. A better charac-
terization of these systemic effects resulting from tumor–
normal cell interactions may yield new tumor markers and
may allow us to delineate new treatment strategies for
women with breast cancer.
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